These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 19743887)
1. A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling. Hisaka A; Kusama M; Ohno Y; Sugiyama Y; Suzuki H Clin Pharmacokinet; 2009; 48(10):653-66. PubMed ID: 19743887 [TBL] [Abstract][Full Text] [Related]
2. [Quantitative Prediction of Drug-Drug Interaction Caused by CYP Inhibition and Induction from In Vivo Data and Its Application in Daily Clinical Practices-Proposal for the Pharmacokinetic Interaction Significance Classification System (PISCS)]. Ohno Y Yakugaku Zasshi; 2018; 138(3):337-345. PubMed ID: 29503426 [TBL] [Abstract][Full Text] [Related]
3. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Ohno Y; Hisaka A; Suzuki H Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375 [TBL] [Abstract][Full Text] [Related]
4. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Ohno Y; Hisaka A; Ueno M; Suzuki H Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297 [TBL] [Abstract][Full Text] [Related]
7. Clinical Trial Data-Driven Risk Assessment of Drug-Drug Interactions: A Rapid and Accurate Decision-Making Tool. Yuan T; Bi F; Hu K; Zhu Y; Lin Y; Yang J Clin Pharmacokinet; 2024 Aug; 63(8):1147-1165. PubMed ID: 39102093 [TBL] [Abstract][Full Text] [Related]
8. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover. Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967 [TBL] [Abstract][Full Text] [Related]
9. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Hisaka A; Ohno Y; Yamamoto T; Suzuki H Pharmacol Ther; 2010 Feb; 125(2):230-48. PubMed ID: 19951720 [TBL] [Abstract][Full Text] [Related]
10. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408 [TBL] [Abstract][Full Text] [Related]
11. Clinically relevant drug interactions between statins and antidepressants. Palleria C; Roberti R; Iannone LF; Tallarico M; Barbieri MA; Vero A; Manti A; De Sarro G; Spina E; Russo E J Clin Pharm Ther; 2020 Apr; 45(2):227-239. PubMed ID: 31587356 [TBL] [Abstract][Full Text] [Related]
12. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes. Preskorn SH J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885 [TBL] [Abstract][Full Text] [Related]
13. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. Xu R; Ge W; Jiang Q Eur J Clin Pharmacol; 2018 Jun; 74(6):755-765. PubMed ID: 29453492 [TBL] [Abstract][Full Text] [Related]
14. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Brown HS; Galetin A; Hallifax D; Houston JB Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215 [TBL] [Abstract][Full Text] [Related]
15. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling. Min JS; Bae SK Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Walzer M; Bekersky I; Blum RA; Tolbert D Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635 [TBL] [Abstract][Full Text] [Related]
18. Quantitative evaluation of drug-drug interaction potentials by in vivo information- guided prediction approach. Chen F; Hu ZY; Jia WW; Lu JT; Zhao YS Curr Drug Metab; 2014; 15(8):761-6. PubMed ID: 25705907 [TBL] [Abstract][Full Text] [Related]
19. How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example. Macaluso M; Nichols AI; Preskorn SH Prim Care Companion CNS Disord; 2015; 17(2):. PubMed ID: 26445693 [TBL] [Abstract][Full Text] [Related]
20. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method. Iga K; Kiriyama A J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]